Purpose: Caudal-related homeobox transcription factor 2 (CDX2) has recently been proposed as a prognostic factor for gastric carcinoma. However and to the best of our knowledge, no previous report has analyzed CDX2 expression in patients with gastric adenocarcinoma receiving neoadjuvant therapy (NAT).
Patients, Materials And Methods: This is a retrospective cohort study to analyze the potential role of CDX2 expression to predict response to NAT and prognosis.
World J Emerg Surg
December 2015